Literature DB >> 8425144

The influence of age and sex on the onset and early course of schizophrenia.

H Häfner1, K Maurer, W Löffler, A Riecher-Rössler.   

Abstract

A new standardised interview for the retrospective assessment of onset and early course of schizophrenia (IRAOS) was used to study the influence of age and sex on time of onset and psychopathology before first admission in 267 schizophrenic patients admitted for the first time. Mean age at onset, according to various operationalised definitions, differed by three to four years between the sexes. The age distribution at the earliest sign of mental disorder showed an early and steep increase until the age of 25 in males, and a delayed and smaller increase in females, with a second peak in women aged 45-79. Schizophrenia began with negative symptoms in 70% of cases, appearing two to six years before admission, and all positive symptoms appearing up to two years before. Both positive and negative symptoms accumulated exponentially. The early course of the disease was similar across age groups, except there was a longer period of negative symptoms before first admission in late-onset schizophrenia in women. The few significant age differences in symptoms were presumably due to general age-dependent reaction patterns like anxiety and depression or the cognitive development of personality, as indicated by an increase in fully elaborated positive symptoms, especially systematised paranoid delusions, with age.

Entities:  

Mesh:

Year:  1993        PMID: 8425144     DOI: 10.1192/bjp.162.1.80

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  106 in total

1.  Gender differences in psychotic disorders with concurrent substance use.

Authors:  Carol L M Caton; Haiyi Xie; Robert E Drake; Gregory McHugo
Journal:  J Dual Diagn       Date:  2014

Review 2.  The development of schizophrenia in late adolescence.

Authors:  Chris E Harrop
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 3.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

4.  One year outcome in first episode schizophrenia. Predictors of relapse.

Authors:  Alp Uçok; Aslihan Polat; Sibel Cakir; Aysun Genç
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-18       Impact factor: 5.270

Review 5.  [Early recognition and intervention for schizophrenia].

Authors:  N Mossaheb; G Wiesegger; G P Amminger; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

6.  The Edinburgh High Risk Study: current status and future prospects.

Authors:  Eve C Johnstone; Kirsten D Russell; Lesley K Harrison; Stephen M Lawrie
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

7.  Covariance modeling of MRI brain volumes in memory circuitry in schizophrenia: Sex differences are critical.

Authors:  Brandon Abbs; Lichen Liang; Nikos Makris; Ming Tsuang; Larry J Seidman; Jill M Goldstein
Journal:  Neuroimage       Date:  2011-04-08       Impact factor: 6.556

8.  Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history.

Authors:  Sarah E Bergen; Colm T O'Dushlaine; Phil H Lee; Ayman H Fanous; Douglas M Ruderfer; Stephan Ripke; Patrick F Sullivan; Jordan W Smoller; Shaun M Purcell; Aiden Corvin
Journal:  Schizophr Res       Date:  2014-02-26       Impact factor: 4.939

Review 9.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

10.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.